393 related articles for article (PubMed ID: 25311384)
1. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Fiorini C; Cordani M; Padroni C; Blandino G; Di Agostino S; Donadelli M
Biochim Biophys Acta; 2015 Jan; 1853(1):89-100. PubMed ID: 25311384
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
4. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
[TBL] [Abstract][Full Text] [Related]
7. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
8. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
9. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis.
Fiorini C; Menegazzi M; Padroni C; Dando I; Dalla Pozza E; Gregorelli A; Costanzo C; Palmieri M; Donadelli M
Apoptosis; 2013 Mar; 18(3):337-46. PubMed ID: 23238993
[TBL] [Abstract][Full Text] [Related]
10. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
11. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
14. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
15. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
Cascalló M; Calbó J; Capellà G; Fillat C; Pastor-Anglada M; Mazo A
Oncology; 2005; 68(2-3):179-89. PubMed ID: 16006755
[TBL] [Abstract][Full Text] [Related]
19. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
Masetto F; Chegaev K; Gazzano E; Mullappilly N; Rolando B; Arpicco S; Fruttero R; Riganti C; Donadelli M
Biochim Biophys Acta Mol Cell Res; 2020 Dec; 1867(12):118824. PubMed ID: 32828758
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
